Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05859074
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:54.025393+00:00
Published At
2025-12-03T00:00:00+00:00
Record Updated At
2025-12-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cutaneous Squamous Cell Carcinoma", "SCC - Squamous Cell Carcinoma", "Basal Cell Carcinoma", "BCC", "BCC - Basal Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Sebaceous Carcinoma", "Extramammary Paget Disease", "Kaposi Sarcoma", "Head and Neck Squamous Cell Carcinoma", "HNSCC", "Adnexal Carcinoma", "Angiosarcoma", "Cutaneous Neoplasm", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Solid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-03"
protocolSection.identificationModule.nctId
"NCT05859074"
protocolSection.identificationModule.officialTitle
"A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cutaneous Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • SCC - Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • BCC (protocolSection.conditionsModule.conditions)
  • BCC - Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Sebaceous Carcinoma (protocolSection.conditionsModule.conditions)
  • Extramammary Paget Disease (protocolSection.conditionsModule.conditions)
  • Kaposi Sarcoma (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • HNSCC (protocolSection.conditionsModule.conditions)
  • Adnexal Carcinoma (protocolSection.conditionsModule.conditions)
  • Angiosarcoma (protocolSection.conditionsModule.conditions)
  • Cutaneous Neoplasm (protocolSection.conditionsModule.conditions)
  • Advanced Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Cancer (protocolSection.conditionsModule.conditions)
  • Refractory Cancer (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.